GLP-1 Receptor Agonists in Stroke Prevention: Evidence of Ischemic Benefit

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are often chosen in part for their cardiovascular benefits. Stroke, however, has rarely been a primary endpoint in the trials establishing those benefits. A narrative review published in Annals of Medicine concluded that pooled evidence suggests reductions in nonfatal and ischemic stroke with GLP-1RAs, although findings from individual trials remain inconsistent.

The authors synthesized cardiovascular outcome trials (CVOTs), meta-analyses, and mechanistic studies of agents including liraglutide, semaglutide, dulaglutide, albiglutide, exenatide, and lixisenatide. Their review considered both clinical stroke outcomes and potential biological pathways underlying cerebrovascular protection.

A Signal Concentrated in Ischemic Stroke

The most consistent evidence came from meta-analyses. In one analysis of 28 randomized trials involving more than 74,000 participants, GLP-1RA use was associated with 17% fewer adverse cerebrovascular events (relative risk [RR], 0.83; 95% CI, 0.76-0.91), driven largely by reductions in nonfatal and ischemic stroke. A separate analysis of 11 CVOTs with more than 82,000 participants reported a 16% relative reduction in total stroke. Neither analysis found a significant reduction in fatal stroke, and pooled evidence did not show a clear benefit for hemorrhagic stroke.

Individual trials were less uniform. Nonfatal stroke was significantly reduced with semaglutide in SUSTAIN-6 (hazard ratio [HR], 0.61; 95% CI, 0.38-0.99) and dulaglutide in REWIND (HR, 0.76; 95% CI, 0.61-0.95). By contrast, other trials of long- and short-acting agents showed no statistically significant reduction in stroke.

The review suggested that long-acting agents may offer more consistent protection through sustained receptor engagement and durable effects on fasting glucose, body weight, and blood pressure. Yet neutral findings with some long-acting drugs suggest that duration of action alone does not explain the differences. Protection also appeared more pronounced in patients with preserved renal function and shorter diabetes duration.

Several Pathways May Contribute to Protection

The authors also described mechanisms that could extend beyond glucose lowering. GLP-1 receptors are present in the brain, where activation of signaling pathways involved in cell survival may suppress inflammatory responses, reduce oxidative stress, and preserve mitochondrial function. Experimental studies also suggest reduced neuronal apoptosis, potentially limiting injury during cerebral ischemia.

Vascular effects may be just as relevant to prevention. GLP-1RAs may improve endothelial function and repair, reduce macrophage-driven inflammation, and stabilize atherosclerotic plaques, potentially lowering thrombotic risk. Together with improvements in weight, blood pressure, and glycemic control, these effects offer a biologic rationale for the apparent emphasis on ischemic rather than hemorrhagic stroke. However, much of the direct neuroprotective evidence remains preclinical.

Where the Evidence Falls Short

Most CVOTs were not designed to evaluate stroke as a primary endpoint. Relatively few stroke events, along with differences in populations and follow-up, limit comparisons across trials. As a narrative review, the synthesis is also susceptible to selection and publication bias. It remains difficult to separate direct neurovascular effects from broader cardiometabolic improvements, and evidence is limited in people without diabetes or with prior stroke or transient ischemic attack.

For clinicians, the review supports GLP-1RAs as part of multifactorial stroke risk reduction in type 2 diabetes, with long-acting agents showing the most consistent evidence. Given the modest absolute benefits, treatment should reflect individual vascular risk, kidney function, tolerability, and access. Trials with stroke as a primary endpoint are needed to clarify who benefits most.

Reference:
Chikatimalla R, Shah A, Shah T, et al. GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers. Ann Med. 2026;58(1):2660386. Published April 18, 2026. doi:10.1080/07853890.2026.2660386